Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Katherine Noble

Physician Assistant London, KY Physician Assistant

NPI 1356394787 CMS profile 11166921

175 City Hill Dr, London, KY 40741

Open in the dashboard

General payments

$8,729

541 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Katherine Noble of London, KY is reported in the CMS Open Payments database as having received $8,729 across 541 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $201 10
2024 General $2,144 114
2023 General $2,390 133
2022 General $2,197 150
2021 General $1,798 134

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Katherine Noble
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Katherine Noble were reported at $201. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Katherine Noble Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,798 $132 $37–$438 $132
2022 $2,197 $155 $48–$522 $149
2023 $2,390 $167 $52–$557 $160
2024 $2,144 $178 $55–$600 $164
2025 $201 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,029 68 payments
  2. Novo Nordisk Inc $919 62 payments
  3. Pfizer Inc. $841 51 payments
  4. Lilly USA, LLC $684 53 payments
  5. Novartis Pharmaceuticals Corporation $603 32 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $506 25 payments
  7. AstraZeneca Pharmaceuticals LP $485 18 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $458 26 payments
  9. Amgen Inc. $378 22 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $333 29 payments
  11. Other $2,492 155 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,729 541 payments
Products named General payments · program years 2021–2025
  1. ELIQUIS $611 33 payments
  2. NURTEC ODT $605 36 payments
  3. RYBELSUS $559 32 payments
  4. Ozempic $555 32 payments
  5. Kerendia $506 25 payments
  6. PAXLOVID $471 28 payments
  7. XIFAXAN $458 26 payments
  8. BREZTRI $384 11 payments
  9. UBRELVY $362 26 payments
  10. FARXIGA $347 9 payments
  11. Other $7,618 491 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 84 drugs

Part D claims

2,394

Median for Physician Assistant: 241

Drug cost

$208,764

Median for Physician Assistant: $4,110

Branded share of claims

26.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 38 $45,074
Trulicity Dulaglutide Brand 17 $30,363
Eliquis Apixaban Brand 34 $28,225
Mounjaro Tirzepatide Brand 20 $25,598
Jardiance Empagliflozin Brand 28 $20,904
Linzess Linaclotide Brand 19 $10,762
Myrbetriq Mirabegron Brand 12 $9,004
Farxiga Dapagliflozin Propanediol Brand 14 $8,777
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 11 $6,769
Raloxifene Hcl Generic 15 $1,471

The 10 drugs with the highest cost, of 84 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$33,719

Of which drugs: $2,838

Medicare patients

253

Average age 75

Services billed

4,022

173 women, 80 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Diabetes 43%
Ischemic heart disease 32%
Osteoporosis 27%
Chronic kidney disease 25%
Atrial fibrillation 23%
Heart failure 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 31 2,840 $291
Injection, methylprednisolone acetate, 80 mg J1040 Office 12 12 $46
Injection, ceftriaxone sodium, per 250 mg J0696 Office 24 108 $30
Injection, ketorolac tromethamine, per 15 mg J1885 Office 14 66 $27
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 14 20 $15

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 38 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $186
$186 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $176
$176 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $171
$171 — —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $134
$134 — —
RYBELSUS
  • Novo Nordisk Inc $112
$112 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 38 with Patron

Records

541 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record